Works matching IS 00099104 AND DT 2023 AND VI 211 AND IP 3
Results: 9
TREX1 cytosolic DNA degradation correlates with autoimmune disease and cancer immunity.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 193, doi. 10.1093/cei/uxad017
- By:
- Publication type:
- Article
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 280, doi. 10.1093/cei/uxad013
- By:
- Publication type:
- Article
Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4).
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 239, doi. 10.1093/cei/uxad005
- By:
- Publication type:
- Article
Comparative studies on mannan and imiquimod induced experimental plaque psoriasis inflammation in inbred mice.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 288, doi. 10.1093/cei/uxad004
- By:
- Publication type:
- Article
Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 269, doi. 10.1093/cei/uxad003
- By:
- Publication type:
- Article
CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 224, doi. 10.1093/cei/uxad002
- By:
- Publication type:
- Article
Gingival transcriptomic patterns of macrophage polarization during initiation, progression, and resolution of periodontitis.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 248, doi. 10.1093/cei/uxac122
- By:
- Publication type:
- Article
Mitochondria as disease-relevant organelles in rheumatoid arthritis.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 208, doi. 10.1093/cei/uxac107
- By:
- Publication type:
- Article
Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage.
- Published in:
- Clinical & Experimental Immunology, 2023, v. 211, n. 3, p. 233, doi. 10.1093/cei/uxac124
- By:
- Publication type:
- Article